Tesamorelin: When the Effect Outlives the Molecule

The short version

Tesamorelin is a lab-made copy of the whole natural hormone that tells the pituitary to release growth hormone — all 44 building blocks, not the shortened 29-block version CJC-1295 is based on.

Its one modification is small: a short fatty group attached to the front end of the chain. That is enough to stop the enzyme that would otherwise cut the hormone apart within minutes. It is not enough to make the molecule stick to a blood protein, so nothing slows the kidneys down. Tesamorelin leaves the blood quickly.

The effects do not. Two weeks of daily use in 13 healthy men raised IGF-1, the growth factor the pituitary signal produces, by 181 micrograms per litre ^[21]. Over a year, visceral fat fell by 18 per cent and stayed down while treatment continued ^[22]. When treatment stopped, the fat came back ^[22].

That is the lesson of this page. A short-lived molecule can produce a long-lived effect, because the effect is carried by a hormone axis rather than by the drug itself. Tesamorelin is an approved prescription medicine, approved for one narrow indication ^[19].

What it is

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone, GHRH(1-44)-NH2, carrying a trans-3-hexenoic acid group conjugated to the N-terminus. It is also catalogued as TH9507. Clinically it is supplied as the acetate salt.

The N-terminal modification is the entire half-life extension strategy, and its target is specific: dipeptidyl peptidase-IV, the enzyme that clips two residues from the front of the native hormone and inactivates it. Blocking the site the enzyme attacks extends plasma stability relative to native GHRH.

What it does not do is anything about renal clearance. There is no fatty di-acid, no albumin linker, no PEG chain and no carrier of any kind. Compare CJC-1295, which starts from a shorter fragment but adds a covalent albumin bond, and semaglutide, which adds a reversible one. Tesamorelin is the minimal intervention in this set: one acyl group, one enzyme defeated.

A numeric plasma half-life for tesamorelin is published in secondary sources including the product labelling. It is not in this digest's 22 references, and so no figure is quoted here. The point the reference set does support is the shape rather than the number: rapid plasma clearance with a persistent downstream signal ^[21][22].

How it works

Tesamorelin binds the growth hormone-releasing hormone receptor on anterior-pituitary somatotrophs, activating the Gs/adenylyl-cyclase/cAMP/PKA cascade and stimulating synthesis and pulsatile secretion of endogenous growth hormone. Growth hormone drives hepatic IGF-1 production, and together they promote lipolysis preferentially in visceral adipose tissue.

Because it amplifies the body's own pulsatile rhythm rather than supplying exogenous growth hormone, its metabolic profile differs from recombinant growth hormone — the same architectural argument that motivates the whole GHRH-analogue class ^[1].

That architecture is also why the pharmacokinetics matter less here than they might elsewhere. The drug's job is to trigger a pituitary event. What follows — growth-hormone secretion, hepatic IGF-1 synthesis, lipolysis in a fat depot — runs on the body's timescale, not the molecule's. A peptide that has already left the plasma can still be driving a measurable change in body composition weeks later.

The measured evidence for that dissociation is direct. In 13 healthy men, tesamorelin 2 milligrams daily for two weeks raised mean overnight growth hormone by 0.5 micrograms per litre, P=0.004, and IGF-1 by 181 micrograms per litre, P<0.0001, while neither fasting glucose, P=0.93, nor insulin-stimulated glucose uptake, P=0.61, was significantly affected ^[21].

What the research shows

Tesamorelin has the second-strongest evidence base on this desk, and the only approval attached to a specific measured endpoint.

A 2026 meta-analysis of five randomised controlled trials in HIV-associated lipodystrophy found tesamorelin reduced visceral adipose tissue by a mean difference of -27.71 square centimetres, 95 per cent confidence interval -38.37 to -17.06, P<0.001; trunk fat by -1.18 kilograms; and hepatic fat fraction by -4.28 per cent; while increasing lean body mass by 1.42 kilograms, all P<0.001, without serious adverse events ^[18].

A six-month randomised controlled trial published in JAMA enrolled 50 antiretroviral-treated adults with HIV, 28 on tesamorelin and 22 on placebo. Tesamorelin 2 milligrams daily produced a treatment effect of -42 square centimetres in visceral fat, P=0.005, and reduced hepatic lipid-to-water percentage by a net -2.9 per cent, P=0.003 ^[20].

The 52-week programme randomised 273 participants to tesamorelin 2 milligrams daily against 137 to placebo. Visceral adipose tissue reduction was sustained at -18 per cent over 52 weeks, P<0.001 against baseline. Visceral fat reaccumulated on discontinuation, and changes in glucose parameters over 52 weeks were not clinically significant ^[22].

All of those trials used daily subcutaneous administration of the same 2-milligram amount ^[20][21][22]. That is a study protocol, reported here as a fact about the trials rather than as a recommendation to anybody.

The reaccumulation finding ^[22] is the most kinetically interesting result in the set. It establishes that the effect is maintained rather than accrued: the visceral fat loss is a steady state held open by continued stimulation of the axis, not a permanent change banked and kept. A molecule with a short plasma half-life produced an effect that persisted for a year and then reversed — which is a statement about the axis, not about the molecule's clearance.

Reported effects, cautions and safety

This desk carries no community-reported signal set for tesamorelin, and the absence is worth stating rather than papering over. Unlike the other three compounds here, tesamorelin has almost no grey-market research-use following to generate forum reports — it is an approved prescription medicine used within a narrow indication, expensive, and injection-only. Where the composed record holds no community-reported material, none is invented to fill the space.

What exists instead is trial data, which is better. The five-trial meta-analysis reported its body-composition benefits without serious adverse events ^[18]. The NIH LiverTox monograph assigns tesamorelin a likelihood score of E — unlikely to cause clinically apparent liver injury — noting no reported attributable liver-injury cases and no de novo serum-enzyme elevations in trials ^[19]. Glucose handling, the obvious concern for anything that raises growth hormone, was measured directly: neither fasting glucose nor insulin-stimulated glucose uptake changed significantly over two weeks in healthy men ^[21], and glucose changes over 52 weeks in the pivotal programme were not clinically significant ^[22].

The cautions in the record are these, and they are questions of scope rather than of acute risk. FDA approval covers reduction of excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy and nothing else, granted in 2010 ^[19]; every other use is off-label and investigational. The pivotal trials were run in HIV-positive adults on antiretroviral therapy, so generalisation to other populations is mechanistically plausible but not established by large randomised trials. Visceral fat reaccumulates within weeks of stopping ^[22]. Growth-hormone-axis stimulation raises IGF-1, a growth factor; trials showed no excess malignancy signal over 52 weeks, but long-term oncologic safety data are limited and active malignancy is a labelled contraindication. Modest glucose perturbation can occur, warranting monitoring in dysglycaemia. Cognitive findings are mixed across trials. Tesamorelin is prohibited in sport under WADA category S2 both in and out of competition. And research-grade material sold for laboratory use lacks the purity and potency oversight of the approved product.

Where it sits on the kinetics map

Tesamorelin is the compound on this desk where reading the plasma curve alone would mislead a reader most badly.

By exposure, it belongs at the short end with ipamorelin. Its only modification defeats one enzyme; nothing binds it to a carrier; it leaves the circulation quickly. By measured effect, it belongs at the long end with CJC-1295: IGF-1 elevated over two weeks of daily administration ^[21], visceral fat down 18 per cent and held there across 52 weeks ^[22].

Both statements are true, because they describe different curves. Pharmacokinetics measures the drug. Pharmacodynamics measures what the drug set in motion. On a hormone axis those two can separate by orders of magnitude, and tesamorelin is the cleanest demonstration of it in this set.

The reversal on discontinuation ^[22] closes the argument neatly. If the effect had been a durable structural change, stopping would not have undone it. It did. What the drug maintains is a signal, and the signal stops when the injections stop — which is a pharmacodynamic fact, and still not a dosing instruction to anyone.